Roche's leading role in oncology confirmed at ASCO
As a leading player in the field of oncology, Roche again had a huge presence at this year's ASCO meeting in Chicago from 30 May to 3 June. The annual meeting of the American Society of Clinical Oncology is a major item on the calendar for cancer specialists the world over. Roche and Genentech attracted high media and medical attention through the clinical trial results they presented. This was particularly true of the innovative cancer drug Avastin and its promising outlook in different indications and of the Phase II clinical trial data presented on pertuzumab in combination with Herceptin for the treatment of HER2-positive breast cancer.
The links below provide an overview of the key news:
A Bloomberg news television interview with Roche Pharma CEO Bill Burns provides an overview of Roche's impact at ASCO. Susan Desmond-Hellmann, Genentech President of Product Development talks about recent findings regarding Avastin. Furthermore, John Johnson, CEO of ImClone, comments on the results of an Erbitux trial for treating lung cancer.
Watch the video clips
Browse the ASCO conference dossier and have a look at the media uptake of the event.
Roche media releases
Study confirms that Avastin significantly increases chance of living without disease progression in metastatic breast cancer (read the release)
Continuing Herceptin treatment prevents disease progression in women with aggressive metastatic breast cancer (read the release)